Streetbeat News

Analyst Ratings

F

GM

STLA

TSLA

The United Auto Workers (UAW) is extending its strike against General Motors (GM) and Ford (F), adding two more assembly plants. This intensifies pressure on the automakers to finalize a new contract agreement. The strike expansion targets Ford’s Chicago Assembly Plant and GM’s Lansing-Delta Assembly Plant, bringing the total number of striking workers to around 25,000. The strike comes at a time of heightened union activity and a shift toward manufacturing electric vehicles in the U.S. Analyst Dan Ives warns that a favorable deal for the union could increase the average EV vehicle price by $3,000-$5,000, impacting units sold and obstructing the future business models of the Detroit Three (GM, Ford, and Stellantis).

Portfolio Pulse from AJ Fabino

September 29, 2023 | 6:20 pm

BIDU

A significant amount of unusual options activity has been observed for Baidu (NASDAQ:BIDU), with a majority of investors taking a bullish stance. Of the 11 strange trades detected, 63% were bullish and 36% were bearish. The total amount for puts was $1,122,138 and for calls was $111,284. Whales have been targeting a price range from $125.0 to $200.0 for Baidu over the last 3 months. Baidu's stock price is currently up 2.71% at $136.04. Bernstein maintains an Outperform rating on Baidu with a price target of $168, while Benchmark and Susquehanna have downgraded their actions to Buy and Positive with price targets of $210 and $175 respectively.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:18 pm

AMGN

A whale investor has taken a bearish stance on Amgen (NASDAQ:AMGN), with 78% of the investors opening trades with bearish expectations. The whales have been targeting a price range from $245.0 to $280.0 for Amgen over the last 3 months. The price of AMGN is down -1.05% at $267.98. Argus Research maintains their Buy rating on Amgen with a price target of $280, while Truist Securities and HSBC have downgraded their actions to Hold and Buy with price targets of $260 and $320 respectively.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:03 pm

TMCI

Treace Medical Concepts (NASDAQ:TMCI) has received 3 bullish and 2 indifferent analyst ratings in the last quarter. The company's average 12-month price target is $26.2, a decrease of 14.57% from the previous average price target of $30.67.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:00 pm

ESTC

Elastic (NYSE:ESTC) has received 16 analyst ratings in the last quarter, with 12 bullish, 4 indifferent, and none bearish. The average 12-month price target for Elastic is $80.56, an increase of 2.49% from the previous average of $78.60.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:00 pm

ALGM

In the last quarter, Allegro Microsystems (NASDAQ:ALGM) received 6 analyst ratings, with 3 being bullish, 2 somewhat bullish, and 1 indifferent. The company's average 12-month price target is $52.0, an increase of 2.62% from the previous average of $50.67.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:00 pm

ICFI

ICF International (NASDAQ:ICFI) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The company's average 12-month price target has increased by 4.04% from $136.00 to $141.5.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:00 pm

NVOS

Hindenburg Research has issued a letter to the board and executive team of Novo Integrated Sciences. The content of the letter is not specified in the news.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 5:58 pm

CHS

Chico's FAS Inc (NYSE:CHS) has agreed to be acquired by private equity firm Sycamore Partners for approximately $1 billion. Telsey Advisory Group analyst Dana Telsey has reiterated a Market Perform rating on CHS shares and raised the price target from $6.00 to $7.60. The analyst views Sycamore as a natural suitor for Chico's due to its track record in the apparel sector and its ownership of MGF Sourcing, a global sourcing and supply chain company. The acquisition is seen as likely to be completed on schedule and at a fair price.

Portfolio Pulse from Shivani Kumaresan

September 29, 2023 | 5:55 pm

CRSP

EDIT

Stifel has upgraded Editas Medicine Inc (NASDAQ:EDIT) from Hold to Buy with a price target of $17, up from $9, citing progress in the company's sickle cell disease candidate, EDIT-301. The analysts also discussed the valuation disparity between Editas and CRISPR Therapeutics AG (NASDAQ:CRSP), and the potential benefits emerging from the IP dispute. Editas shares are up 11.30% at $7.70.

Portfolio Pulse from Vandana Singh

September 29, 2023 | 5:40 pm